154 related articles for article (PubMed ID: 7744644)
1. Prognostic factors for treatment of malignant lymphoma in dogs.
Teske E; van Heerde P; Rutteman GR; Kurzman ID; Moore PF; MacEwen EG
J Am Vet Med Assoc; 1994 Dec; 205(12):1722-8. PubMed ID: 7744644
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for treated canine malignant lymphoma.
Kiupel M; Teske E; Bostock D
Vet Pathol; 1999 Jul; 36(4):292-300. PubMed ID: 10421095
[TBL] [Abstract][Full Text] [Related]
3. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma.
MacEwen EG; Rosenthal RC; Fox LE; Loar AS; Kurzman ID
J Vet Intern Med; 1992; 6(4):230-4. PubMed ID: 1522554
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
6. Antitumor enzyme: polyethylene glycol-modified asparaginase.
Wada H; Imamura I; Sako M; Katagiri S; Tarui S; Nishimura H; Inada Y
Ann N Y Acad Sci; 1990; 613():95-108. PubMed ID: 2076022
[No Abstract] [Full Text] [Related]
7. Polyethylene glycol-L-asparaginase versus native L-asparaginase in canine non-Hodgkin's lymphoma.
Teske E; Rutteman GR; van Heerde P; Misdorp W
Eur J Cancer; 1990; 26(8):891-5. PubMed ID: 2145933
[TBL] [Abstract][Full Text] [Related]
8. Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival.
Valli VE; Kass PH; San Myint M; Scott F
Vet Pathol; 2013 Sep; 50(5):738-48. PubMed ID: 23444036
[TBL] [Abstract][Full Text] [Related]
9. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma.
Piek CJ; Rutteman GR; Teske E
Vet Q; 1999 Apr; 21(2):44-9. PubMed ID: 10321012
[TBL] [Abstract][Full Text] [Related]
11. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
MacDonald VS; Thamm DH; Kurzman ID; Turek MM; Vail DM
J Vet Intern Med; 2005; 19(5):732-6. PubMed ID: 16231719
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of clinical presentation, cytological picture and response to treatment in canine centroblastic lymphoma.
Kliczkowska-Klarowicz K; Jagielski D; Czopowicz M; Sapierzyński R
Pol J Vet Sci; 2021 Mar; 24(1):101-107. PubMed ID: 33847104
[TBL] [Abstract][Full Text] [Related]
13. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
Ponce F; Magnol JP; Ledieu D; Marchal T; Turinelli V; Chalvet-Monfray K; Fournel-Fleury C
Vet J; 2004 Mar; 167(2):158-66. PubMed ID: 14975390
[TBL] [Abstract][Full Text] [Related]
16. Asparaginase and MOPP treatment of dogs with lymphoma.
Brodsky EM; Maudlin GN; Lachowicz JL; Post GS
J Vet Intern Med; 2009; 23(3):578-84. PubMed ID: 19645842
[TBL] [Abstract][Full Text] [Related]
17. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma: 96 cases (1993-2006).
Abbo AH; Lucroy MD
J Am Vet Med Assoc; 2007 Dec; 231(12):1836-42. PubMed ID: 18081522
[TBL] [Abstract][Full Text] [Related]
18. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
19. Influence of a cyclic combination chemotherapeutic protocol on primary haemostasis in dogs suffering from malignant lymphoma.
Eberle N; Mischke R
Vet J; 2010 Mar; 183(3):298-304. PubMed ID: 19185520
[TBL] [Abstract][Full Text] [Related]
20. A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma.
MacEwen EG; Rosenthal R; Matus R; Viau AT; Abuchowski A
Cancer; 1987 Jun; 59(12):2011-5. PubMed ID: 3567863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
